MannKind (MNKD) Could Be 62% Undervalued After New Furoscix Data

Why Furoscix ReadyFlow matters for MannKind investors

MannKind (MNKD) just pushed fresh Furoscix ReadyFlow data into the spotlight at the Heart Failure Society of America meeting, sharpening the real world profile of its newly approved furosemide autoinjector for outpatient heart failure and chronic kidney disease care.

The upbeat ReadFlow story is landing against a weak tape for MannKind. The share price is US$3.04 after falling 14.1% over the past 30 days and 45.7% year to date, while the 1 year total shareholder return of 44.4% decline shows longer term holders are still working through a meaningful drawdown even as new product catalysts hit the headlines.

Look beyond MannKind to see how other pressured healthcare names with solid fundamentals may be setting up for a potential rebound with our hand-picked 33 high quality undervalued stocks.

The share slide and a price almost 60% below the average analyst target put MannKind at a clear discount. The real debate now is whether that gap reflects opportunity or justified caution around profits and execution.

Most Popular Narrative: 61.9% Undervalued

MannKind’s most followed valuation story pegs fair value at $7.97, well above the last close at $3.04. This puts a spotlight on whether the current discount lines up with the business shift toward owned products like Furoscix ReadyFlow.

The shift toward a more diversified, product led model is now visible in the mix of Q2 2026 revenue. Afrezza and Furoscix grew 111% year over year excluding collaboration services and 27% quarter over quarter, while royalty revenue was broadly flat. This suggests owned products are gaining weight in the P&L and can have a growing influence on gross margin and earnings over time.

See why 10 investors see MannKind as 62% undervalued.

Result: Fair Value of $7.97 (UNDERVALUED)

Still, MannKind’s story rests on turning a US$43.6 million loss into sustainable profits, and on Afrezza and Furoscix delivering against those ambitious analyst assumptions.

Find out about the key risks to this MannKind narrative.

Next Steps

Sentiment around MannKind is mixed, with clear concerns and some genuine bright spots. Act while the details are fresh and weigh both sides for yourself by reviewing the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond MannKind?

If MannKind has your attention, do not stop there. Use the same structured approach across other opportunities so your watchlist reflects the choices you actually want.

• Target resilience by focusing on financially robust businesses through the list of solid balance sheet and fundamentals (25 results).
• Hunt for mispriced quality by scanning the 20 high quality undiscovered gems.
• Dial down volatility risk by concentrating on the 32 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com